Global Giant Cell Arteritis Treatment Market Report and Forecast 2023-2028

According to the report, the global giant cell arteritis treatment market attained a value of USD 141 million in 2022. Aided by the increasing prevalence of giant cell arteritis (GCA) and the growing geriatric population, the market is projected to further grow at a CAGR of 5.1% between 2023 and 2028 to reach a value of USD 190.06 million by 2028.

Giant cell arteritis, also known as temporal arteritis, is an autoimmune disease characterised by inflammation of the medium and large arteries, predominantly affecting the elderly population. This condition can cause severe complications, including permanent vision loss and stroke, if left untreated. The treatment for GCA primarily involves the use of corticosteroids, immunosuppressive drugs, and biological agents to reduce inflammation and alleviate symptoms.

The increasing prevalence of GCA is one of the primary factors driving the global giant cell arteritis treatment market growth. The rising geriatric population worldwide is more susceptible to autoimmune disorders like GCA, which in turn, is expected to lead to a higher demand for effective treatment options.

The growing awareness of GCA and its potential complications is another key factor propelling market growth. As healthcare professionals and patients become more aware of the symptoms, diagnosis, and treatment options for GCA, the demand for GCA treatments is likely to increase. Additionally, advancements in diagnostic techniques have facilitated early detection and diagnosis of GCA, further boosting the giant cell arteritis treatment market size.

Moreover, the increasing focus on research and development of novel treatment options for GCA is expected to contribute to the growth of the giant cell arteritis treatment market. Pharmaceutical companies and researchers are actively exploring new therapeutic approaches, such as biologic agents and targeted immunotherapies, to improve treatment outcomes and reduce side effects associated with conventional therapies like corticosteroids.

Improvements in healthcare infrastructure, particularly in developing regions is expected to surge the growth of the market for giant cell arteritis treatment. As more governments of various countries expand their healthcare capabilities, there is increased support for treatment of specific forms of arteritis, including giant cell arteritis. Countries with significant geriatric populations specifically are anticipated to enhance their treatment capabilities for giant cell arteritis, supporting the growth of the giant cell arteritis treatment market.

Market Segmentation

The market can be divided based on treatment type, end use, and region.

Market Breakup by Treatment Type

• Corticosteroid Therapy
• Others (Monoclonal Antibody)

Market Breakup by End Use

• Hospitals
• Clinics
• ASC’s
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global giant cell arteritis treatment companies. Some of the major key players explored in the report are as follows:

• F. Hoffmann-La Roche Ltd
• Kiniksa Pharmaceuticals, Ltd
• Teva Pharmaceutical Industries Ltd
• Tianjin Tianyao Pharmaceutical Co., Ltd
• Others

*The publisher always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.